The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
On a similar note the earnings in March is going to be a big deciding factor on the movement on this stock. Good earnings growth and strong future prediction will most likely spark a bull run. However the next big factor that will affect BATM share price and the market as a whole is BoE interest rates hikes. If BoE continue to hike it will increase downward pressure on ALL equities as bonds become more attractive. A question for you all: inflation continues to remain sky high, how many rate hikes do you think the monetary policy committee will perform this year?
I think revenue projections will be hard to estimate. Not all of the companies income streams are publicised but I have rough figured. Also the further away the date is the less accurate mine (and others) predictions will be as external factors can play a huge role in the market (as we have seen in recent times). Nevertheless I believe the revenue in the upcoming years will be strong.
FY21 revenue prediction $150 million (I believe revenue will continue to grow at a slower rate)
FY22 revenue prediction $180 million (projects will start becoming profitable)
These are my predictions and may be a bit optimistic however I think the diverse portfolio gives them a lot of options in the future. Let me know what you guys think of my projections.
Was reading through the rat's blog again this morning and just wanted to highlight the inaccuracy of it. The blog said that "the profit earned by Celitron on these ventilators was enormous and totally distortive to BATM’s group performance for 2020. Celitron contributed about 60% of group net income and all of its free cash flow. "
However when I dug deeper and did some further research I found that BATM stated that during the COVID period the profitability of all the products in the Bio Med division increased. The profitability of diagnostic products also increased to about 50% (much more than in previous years) and continued to do so in the first half of 2021.
Personally I find it hilarious when shorters misleading/inaccurate information goes public
Agricore,
I couldn't agree more. When I first read the rat's blog i panicked and thought I had to sell. But after doing some further research I began to question the validity of the blog. Thankfully I didn't sell my position. Your insight was very informative, I think everyone that read this chat should take the time to read your post.
Resistance1,
Glad that other investors are seeing that BATM's portfolio includes a mix of established and novel technologies, and targets a range of sub-segments, customer types and geographical markets. I hadn't done as much research into the depth of their portfolio but this is an interesting insight. Just goes to show the potential BATM have in the long run. If I'm honest I see this dip from the shorters as a blessing in disguise as it gives us the opportunity to increase our position at a lower price even thought the company continues to excel.
Seems like a quiet day today for BATM. My guess is the share price will fluctuate around the 50 mark until earnings come out. This will be the deciding factor for BATM. If earnings are stronger than expected shorters will be in trouble. Ennismore will most likely have their second huge loss in two years because people will see the attractiveness of holding BVC
Ennismore will be praying for weak earnings. My guess is that if earnings are positive (as they have been in recent years) the shorters will have to sell their position as they know BATM will start getting traction. If the shorters sell there is a posibility BATM could go back to the 100 mark. Obviously earnings are not the only thing that will affect this outcome. Interest rate hikes will also have a big part to play for how the markets as a whole react in the upcoming months.
Kenwrong, I agree. If investors look at the fundamentals most will see this as a buying opportunity. BATM's earnings are often seen to outperform expectations as they continue to grow massively. $12.26 million profit after tax, up from $4.3 million the year before. The 7% increase today was just the start. BATM earnings come out on the 9th of March, and I see no reason why revenue will not of grown exponentially as it has done in prior years. If revenue beats expectations, we could see a generous pop in price.
However I disagree with your last statement. You can beat the shorters. In fact those very same shorters at Ennismore got beat last year and ended up getting massively burned, loosing millions in the process. They have used this spurious report to gain some momentum in their shorting position from novice investors. Clearly they are not confident with the fundamentals otherwise this would not be the case. In my opinion it seems crazy to short a stock with excellent fundamentals and growing earnings. In the long-run BATM will come out a lot stronger. The truth always comes out.
Darton, I think you summed it up perfectly. Looking at the past month on the charts makes it seem a lot worse than it actually is. But this has its upsides as it means a bounce back in share price is likely in the short term. As most know the buy back would result in fewer shares in circulation and you don't need to be a genius to know that less supply and the same (if not more demand) results in a higher price. Basic economics.
Bluerill,
Couldn't agree more. The blogger shows distinct lack of knowledge of accounting and audit standards and principles throughout the report. A biased report to serve the purpose of short position. Clearly Ennismore haven't learned from their last short position where they got burnt and lost millions. I guess they thought that they could attract the attention of novice investors and scare them into selling. Personally I find it hilarious that Ennismore have resorted to funding a blogger to support their investment decisions.
Recent updates on BATM:
- Strong balance sheet ($12.26 million profit after tax, up from $4.3 million the year before)
- Diversification (BATM’s portfolio includes a mix of established and novel technologies, and targets a range of sub-segments, customer types and geographical markets)
- Return to shareholders (Reinstated dividend policy from FY 2020)
The fundamentals of this tech company illustrate that the intrinsic value of BATM is much higher than the share price. Potential money to be made on this arbitrage in price. Would love to hear more of everyone's opinion on this confusing market valuation.
Another classic short selling campaign from selfish hedge funds with greedy intentions, laughable if you ask me. Do I even have to mention that false information is the first thing regulators look for in terms of manipulating the market. Novice investors who fail to do their research will jump on this so called 'opportunity' before verifying the credibility of the source. I myself am not invested in BATM however see this as a potential 'buy the dip' moment as Goldman Sachs stated in their most recent podcast.